See more : Yuyu Pharma, Inc. (000227.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Venture Life Group plc (VLG.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Venture Life Group plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- The J. M. Smucker Company (0L7F.L) Income Statement Analysis – Financial Results
- Charlie’s Holdings, Inc. (CHUC) Income Statement Analysis – Financial Results
- Fredun Pharmaceuticals Limited (FREDUN.BO) Income Statement Analysis – Financial Results
- American Potash Corp. (APCOF) Income Statement Analysis – Financial Results
- Pingify International Inc. (PGFY) Income Statement Analysis – Financial Results
Venture Life Group plc (VLG.L)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.venture-life.com
About Venture Life Group plc
Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, dermo-cosmetics, and topical products for the ageing population in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. It operates through Venture Life Brands and Customer Brands segments. The company offers neurology products, including NeuroAge, NeuroAge Sleep, and NeuroAge NRG food supplements to enhance alertness, cognitive function, and mental performance in healthy brain; and Original Bioscalin to treat and prevent hair loss, hair thinning, and baldness. It also provides Fungal Nail Solution, which helps to treat and prevent fungal infections; and Fungal Nail Cleanser for the hygiene of hands and feet prone to fungal nail infections under the Myco Clear brand name. In addition, the company offers UltraDEX product for bad breath; Dently Dual Action, a mouthwash, which lifts and removes plaque and bacteria from the teeth and gums; and Procto-eze plus for anal irritation, including haemorrhoids condition. Further, it provides women healthcare products comprising vonalei bacterial vaginosis, a refreshing gel; vonalei Vaginal Atrophy, a vaginal cream; vonalei candidiasis, a soothing cream-gel for thrush; and vonalei intimate cleansing foam. Additionally, it offers Cleansing Foam, Cleansing Cream, and Serum under the Rosa calma brand name; and skincare ranges to hydrate, nourish, and recondition the skin, as well as to prevent the lines and wrinkles under the Lubatti Classic and the Lubatti Anti-age brand names. The company sells its products through a network of international partners, retail pharmacies, as well as grocery multiple retailers. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 51.41M | 43.98M | 32.76M | 30.08M | 20.21M | 18.77M | 16.05M | 14.28M | 9.08M | 7.19M | 486.00K | 292.00K |
Cost of Revenue | 31.26M | 26.32M | 19.80M | 17.23M | 12.20M | 11.48M | 9.58M | 8.79M | 6.07M | 4.54M | 301.00K | 173.00K |
Gross Profit | 20.15M | 17.67M | 12.96M | 12.85M | 8.00M | 7.29M | 6.47M | 5.49M | 3.00M | 2.65M | 185.00K | 119.00K |
Gross Profit Ratio | 39.19% | 40.17% | 39.55% | 42.72% | 39.61% | 38.83% | 40.31% | 38.45% | 33.09% | 36.92% | 38.07% | 40.75% |
Research & Development | 303.00K | 206.00K | 316.00K | 548.00K | 194.00K | 237.00K | 387.00K | 426.00K | 326.00K | 493.00K | 48.00K | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.18M | 906.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 8.76M | 8.90M | 6.71M | 6.76M | 5.12M | 4.54M | 4.38M | 4.38M | 3.44M | 3.37M | 1.18M | 906.00K |
Other Expenses | 7.80M | 14.34M | 10.39M | 8.72M | 6.52M | 6.07M | 0.00 | 65.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 16.86M | 14.34M | 10.39M | 8.72M | 6.52M | 6.07M | 5.89M | 5.78M | 4.45M | 3.82M | 1.18M | 906.00K |
Cost & Expenses | 48.12M | 40.66M | 30.19M | 25.95M | 18.72M | 17.55M | 15.47M | 14.57M | 10.53M | 8.36M | 1.48M | 1.08M |
Interest Income | 15.00K | 1.00K | 89.00K | 54.00K | 152.00K | 0.00 | 0.00 | 0.00 | 152.00K | 156.00K | 1.00K | 0.00 |
Interest Expense | 2.18M | 1.52M | 514.00K | 333.00K | 68.00K | 341.00K | 518.00K | 644.00K | 95.00K | 81.00K | 25.00K | 1.00K |
Depreciation & Amortization | 6.64M | 5.39M | 3.70M | 1.99M | 1.37M | 1.38M | 1.19M | 1.04M | 829.00K | 647.00K | 60.00K | 56.00K |
EBITDA | 9.95M | 7.61M | 5.16M | 5.60M | 2.80M | 2.60M | 1.77M | 573.00K | -713.00K | -815.00K | -1.04M | -731.00K |
EBITDA Ratio | 19.35% | 19.81% | 19.41% | 20.52% | 14.86% | 13.87% | 11.03% | 5.27% | -5.14% | -5.09% | -191.77% | -250.34% |
Operating Income | 3.29M | 3.33M | 2.66M | 3.56M | 1.28M | 1.05M | 581.00K | -465.00K | -1.69M | -1.62M | -1.10M | -787.00K |
Operating Income Ratio | 6.40% | 7.56% | 8.11% | 11.82% | 6.32% | 5.60% | 3.62% | -3.26% | -18.66% | -22.51% | -225.93% | -269.52% |
Total Other Income/Expenses | -2.17M | -1.52M | -425.00K | -279.00K | 84.00K | -341.00K | -518.00K | -644.00K | 57.00K | 75.00K | -24.00K | -1.00K |
Income Before Tax | 1.12M | 706.00K | 946.00K | 3.28M | 1.36M | 710.00K | 63.00K | -1.11M | -1.64M | -1.54M | -1.12M | -788.00K |
Income Before Tax Ratio | 2.18% | 1.61% | 2.89% | 10.89% | 6.74% | 3.78% | 0.39% | -7.77% | -18.03% | -21.46% | -230.86% | -269.86% |
Income Tax Expense | 202.00K | 186.00K | -1.46M | 908.00K | 458.00K | 474.00K | 430.00K | 260.00K | 124.00K | 27.00K | -41.00K | 0.00 |
Net Income | 921.00K | 520.00K | 2.40M | 2.37M | 904.00K | 236.00K | -367.00K | -1.37M | -1.76M | -1.57M | -1.08M | -788.00K |
Net Income Ratio | 1.79% | 1.18% | 7.33% | 7.87% | 4.47% | 1.26% | -2.29% | -9.59% | -19.40% | -21.84% | -222.43% | -269.86% |
EPS | 0.01 | 0.00 | 0.02 | 0.03 | 0.01 | 0.00 | -0.01 | -0.04 | -0.05 | -0.06 | -0.07 | -0.05 |
EPS Diluted | 0.01 | 0.00 | 0.02 | 0.03 | 0.01 | 0.00 | -0.01 | -0.04 | -0.05 | -0.06 | -0.07 | -0.05 |
Weighted Avg Shares Out | 126.50M | 126.26M | 125.83M | 86.40M | 83.83M | 62.58M | 36.89M | 36.46M | 34.45M | 26.17M | 16.14M | 16.14M |
Weighted Avg Shares Out (Dil) | 133.64M | 133.39M | 133.82M | 93.42M | 89.38M | 62.58M | 36.89M | 36.46M | 34.45M | 26.17M | 16.14M | 16.14M |
Source: https://incomestatements.info
Category: Stock Reports